The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRSN | -83.87% | -98.43% | -56.41% | -97% |
| S&P | +14.49% | +91.09% | +13.83% | +181% |
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
The company reported disappointing clinical results.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.06M | 33.3% |
| Gross Profit | $2.77M | 46.5% |
| Gross Margin | 90.61% | 8.2% |
| Market Cap | $36.93M | -85.0% |
| Market Cap / Employee | $0.36M | 0.0% |
| Employees | 102 | -17.1% |
| Net Income | -$24.30M | -0.1% |
| EBITDA | -$20.29M | 19.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $77.45M | 31.3% |
| Accounts Receivable | $0.27M | -83.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $20.62M | 72.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -56.15% | -13.4% |
| Return On Invested Capital | -618.71% | -498.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$22.60M | -3.4% |
| Operating Free Cash Flow | -$22.60M | -3.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 221.37 | -17.39 | -1.39 | -0.69 | -107.91% |
| Price to Sales | 6.66 | 4.36 | 1.26 | 1.06 | -87.09% |
| Price to Tangible Book Value | 687.84 | 4187.31 | -104.66 | -29.88 | -113.60% |
| Enterprise Value to EBITDA | -9.28 | -4.91 | 1.45 | 0.98 | -121.27% |
| Return on Equity | -292.2% | -213.3% | -280.3% | -505.1% | 89.74% |
| Total Debt | $31.51M | $28.65M | $24.62M | $20.62M | -36.17% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
